Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith

a technology of hyaluronic acid and cosmetics, which is applied in the direction of drug compositions, biocide, dermatological disorders, etc., can solve the problems of wrinkles, decreased amount and quality, irregular distribution of melanin in the epidermis, etc., and achieves the effect of reducing the number, increasing the bioavailability of hyaluronic acid, and high efficacy in filling

Inactive Publication Date: 2009-01-15
GALDERMA RES & DEV SNC
View PDF5 Cites 109 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0030]When a pharmaceutical or cosmetic composition or preparation for topical and / or parenteral application comprises, formulated into a physiologically acceptable medium, hyaluronic acid, and at least one retinoid and / or salts thereof and / or derivatives thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, it clearly increases the bioavailability of the hyaluronic acid, it makes it possible to space out the applications and to reduce the number thereof and it is highly effective in filling wrinkles, fine lines, fibroblast depletions and any scars.

Problems solved by technology

The distribution of melanin in the epidermis is also irregular, subsequent to melanosome transfer problems.
However, it decreases in amount and in quality with age, leading to drying out of the skin, which becomes wrinkled.
However, because the bioavailability of hyaluronic acid is too low after injection and its injection frequency is too high, it cannot be used as such.
However, these modifications affect the physicochemical characteristics and the biological properties of hyaluronic acid, and also its outcome after administration.
Furthermore, the bioavailability of these hyaluronic acid derivatives, although better than that of natural hyaluronic acid, still remains too short.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith
  • Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith

Examples

Experimental program
Comparison scheme
Effect test

example 1

Inhibitory Effect of Glycyrrhizin (GLZ) on Hyaluronidase Activity of Bovine Origin

[0097]Determination of the IC50 of GLZ, with or without Pre-Incubation at 37° C.:

[0098]GLZ, at various concentrations, is or is not pre-incubated for 20 minutes at 37° C. in the presence of the enzyme. The enzyme reaction is triggered by adding the hyaluronic acid solution (time T0). After incubation for 20 minutes, the non-hydrolyzed hyaluronic acid is precipitated by adding acidic bovine albumin solution.

[0099]In order to verify that the pre-incubation step has no effect on the stability of the hyaluronidase, an aliquot of a solution of the enzyme is placed at 37° C. for 20 minutes. Another aliquot is conserved in an ice bath for 19 minutes, and is then incubated at 37° C. for 1 minute. A solution of hyaluronic acid is then added to each aliquot (T0). After incubation for 15, or 45 minutes, the non-hydrolyzed hyaluronic acid is precipitated by addition of acidic bovine albumin solution.

[0100]Measurem...

example 2

Inhibitory Effect of the “GLZ+Pentamer (NAG-Glucuronic Acid)5+Retinol” Combination on the Neosynthesis of Hyaluronic Acid by Normal Human Keratinocytes

[0105]According to the prior art, it is accepted that an equilibrium pre-exists from the neosynthesis and the degradation of hyaluronic acid. In other words, the neosynthesis of hyaluronic acid is a reflection of its degradation: measuring the variations in one therefore amounts to measuring the variations in the other. For reasons of technical simplicity, the change in neosynthesis of hyaluronic acid in the presence of the “GLZ+pentamer (NAG-glucuronic acid)5+retinol” combination is measured, relative to the corresponding control.

[0106]The adult human keratinocytes (NHK) are isolated from a fragment of human skin collected after an abdominoplasty operation (subject CAOL, 38 years old).

[0107]The NHK are cultured to confluence as a monolayer in 24-well plates and sub-cultured. The NHK are used following the third passage.

[0108]The cult...

example 3

Composition No. 1

[0134]Injectable solution No. 1 containing the 4 components:

[0135]This composition is prepared in a manner that is conventional for those skilled in the art:

Hyaluronic acid2%Glycyrrhizin0.02%Pentamer (NAC-glucuronic acid)50.002%Retinol0.00001%Waterqs 100%

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Compositionaaaaaaaaaa
Acidityaaaaaaaaaa
Degradation propertiesaaaaaaaaaa
Login to View More

Abstract

Pharmaceutical / cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and / or salt and / or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars.

Description

CROSS-REFERENCE TO PRIORITY / PCT APPLICATIONS[0001]This application claims priority under 35 U.S.C. § 119 of FR 0513055, filed Dec. 21, 2005, and is a national phase of PCT / FR 2006 / 051391, filed Dec. 19, 2006 and designating the United States (published in the French language on Jul. 5, 2007 as WO 2007 / 074288 A1; the title and abstract were also published in English), each hereby expressly incorporated by reference in its entirety and each assigned to the assignee hereof.BACKGROUND OF THE INVENTION[0002]1. Technical Field of the Invention[0003]The present invention relates to preparations for topical and / or parenteral administration, comprising hyaluronic acid formulated into a physiologically acceptable medium, to processes for the production of such preparations, and to uses thereof as a medicament, such preparations being especially useful for the treatment of dermatological conditions and afflictions, in particular for the treatment of wrinkles, fine lines, fibroblast depletions ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/728A61P17/00A61K8/73A61Q19/00A61P17/02A61P41/00
CPCA61K8/63A61K8/342A61K8/735A61K9/0014A61K9/0019A61K31/07A61K31/702A61K31/704A61K31/728A61K47/12A61K47/26A61Q19/00A61Q19/08A61K8/671A61K47/28A61K47/10A61K8/60A61K2300/00A61P17/00A61P17/02A61P41/00
Inventor MOUTET, MARCYADAN, JEAN-CLAUDE
Owner GALDERMA RES & DEV SNC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com